nexviazyme – Lab DB

Pharmaceutical R&D

Sanofi’s Nexviazyme Demonstrates Promising Results in Infants with Infantile-Onset Pompe Disease, Paving Way for Potential Label Expansion

Teuku Ryan Jul 1, 2026 0

Sanofi’s groundbreaking treatment for Pompe disease, Nexviazyme (avalglucosidase alfa), has achieved a significant milestone with the successful completion of the…

Sanofi’s Nexviazyme Demonstrates Promising Results in Infants with Infantile-Onset Pompe Disease, Paving Way for Potential Label Expansion

YOU MAY HAVE MISSED

CEPI Fast-Tracks Ebola Vaccine Candidates from IAVI, Moderna, and Oxford

Sanofi’s Nexviazyme Demonstrates Promising Results in Infants with Infantile-Onset Pompe Disease, Paving Way for Potential Label Expansion

Science News: Empowering Public Understanding of Science, Medicine, and Technology Since 1921

AI-Driven Breakthrough Uncovers Novel Antibiotics to Combat the Global Threat of Drug-Resistant Gonorrhea